EYEN vs. JAGX, BCLI, PHXM, CSCI, AIMD, AEON, RLMD, TSBX, EDSA, and PBM
Should you be buying Eyenovia stock or one of its competitors? The main competitors of Eyenovia include Jaguar Health (JAGX), Brainstorm Cell Therapeutics (BCLI), PHAXIAM Therapeutics (PHXM), COSCIENS Biopharma (CSCI), Ainos (AIMD), AEON Biopharma (AEON), Relmada Therapeutics (RLMD), Turnstone Biologics (TSBX), Edesa Biotech (EDSA), and Psyence Biomedical (PBM). These companies are all part of the "pharmaceutical products" industry.
Eyenovia vs.
Jaguar Health (NASDAQ:JAGX) and Eyenovia (NASDAQ:EYEN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations, profitability and community ranking.
Jaguar Health has a net margin of -360.13% compared to Eyenovia's net margin of -114,639.41%. Jaguar Health's return on equity of -326.62% beat Eyenovia's return on equity.
In the previous week, Jaguar Health had 3 more articles in the media than Eyenovia. MarketBeat recorded 3 mentions for Jaguar Health and 0 mentions for Eyenovia. Jaguar Health's average media sentiment score of 0.10 beat Eyenovia's score of 0.00 indicating that Jaguar Health is being referred to more favorably in the media.
Jaguar Health received 1661 more outperform votes than Eyenovia when rated by MarketBeat users. Likewise, 88.73% of users gave Jaguar Health an outperform vote while only 64.44% of users gave Eyenovia an outperform vote.
Eyenovia has lower revenue, but higher earnings than Jaguar Health.
12.0% of Jaguar Health shares are owned by institutional investors. Comparatively, 25.8% of Eyenovia shares are owned by institutional investors. 0.0% of Jaguar Health shares are owned by insiders. Comparatively, 7.1% of Eyenovia shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Eyenovia has a consensus target price of $2.00, suggesting a potential upside of 18.34%. Given Eyenovia's stronger consensus rating and higher probable upside, analysts plainly believe Eyenovia is more favorable than Jaguar Health.
Jaguar Health has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Comparatively, Eyenovia has a beta of 1.24, suggesting that its stock price is 24% more volatile than the S&P 500.
Summary
Jaguar Health beats Eyenovia on 8 of the 14 factors compared between the two stocks.
Get Eyenovia News Delivered to You Automatically
Sign up to receive the latest news and ratings for EYEN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eyenovia Competitors List
Related Companies and Tools
This page (NASDAQ:EYEN) was last updated on 2/22/2025 by MarketBeat.com Staff
